Business
Larimar Therapeutics raises USD 100m in upsized underwritten public offering
U.S.-based Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced the pricing of an upsized underwritten public offering of common stock with aggregate gross...
Sanofi acquires global rights to rovadicitinib from Sino Biopharmaceutical in up to USD 1.53b deal
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Hong Kong-listed Sino Biopharmaceutical Limited (HKEX: 1177), has entered into an...
Nasus Pharma raises USD 15m in private placement financing
Nasus Pharma Ltd. (NYSE: NSRX) announced a USD 15.0 million private placement financing on February 10, 2026, targeting the advancement of its intranasal...
Oryon Cell Therapies Exits Stealth With USD 42m Series A for Parkinson's Cell Therapy
Oryon Cell Therapies, a clinical-stage company headquartered in Belmont, Massachusetts, has emerged from stealth with USD 42 million in total financing...
Apertura Gene Therapy and Viralgen partner to manufacture blood-brain barrier-crossing AAV capsid for CNS gene therapy
Apertura Gene Therapy and Viralgen, a contract development and manufacturing organization based in San Sebastián, Spain, have entered a manufacturing...
Hansa Biopharma Raises USD 30 Million Convertible Note to Fund Imlifidase US Launch
Lund, Sweden-based Hansa Biopharma AB, a commercial-stage biopharmaceutical company developing immunomodulatory therapies for patients with acute or complex...
Avenue Therapeutics licenses ATX-04 clenbuterol from Duke University for Pompe disease treatment
Avenue Therapeutics, Inc. (OTC: ATXI), a Miami-headquartered specialty pharmaceutical company majority-owned by Fortress Biotech, Inc. (Nasdaq: FBIO),...
Evogene and Queensland University of Technology Partner on AI-Driven Cancer Drug Discovery for Lung Cancer
Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN), a Rehovot, Israel-based computational chemistry company, and the Queensland University of Technology (QUT) in...
Collegium acquires ADHD drug AZSTARYS from Corium Therapeutics for USD 650m plus milestones
Collegium Pharmaceutical, based in Stoughton, Massachusetts, announced a definitive agreement to acquire AZSTARYS from Corium Therapeutics Holdings for USD...
Sentynl Therapeutics licenses PRG S&T's oral progeria drug Progerinin for clinical development
Sentynl Therapeutics, a U.S.-based subsidiary of Zydus Lifesciences, has entered into a licensing agreement with South Korean rare disease company PRG S&T...
JAX-NYSCF Collaborative and GSS plc 5-Year Strategic Partnership in Neurodegenerative Disease Research
The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) and GSK plc (LSE: GSK) have entered a five-year strategic research...
Pinnacle raises USD 89m in Series B cash for oral peptide programs
Pinnacle Medicines, a biotechnology company headquartered in Shanghai and Doylestown, Pennsylvania, focused on oral peptide drug development, has closed an...
Novartis strengthens allergy leadership via USD 2b Excellergy acquisition
Novartis has entered into an agreement to acquire Excellergy, Inc., a private US-based biotech developing next-generation anti-IgE therapies, for up to USD...
BioVie spinoff Option Therapeutics moving towards IPO for USD 21.8m
Option Therapeutics Inc. (NYSE American: OPTN), a clinical-stage biopharmaceutical company incorporated in Delaware, filed for an initial public offering of...
Evogene and Shanghai Lishan Biopharmaceuticals Seal USD Global Microbiome Cancer Therapeutic Licensing Deal
Evogene Ltd. and Shanghai Lishan Biopharmaceuticals Co. have [announced an exclusive worldwide licensing agreement](https://www.prnewswire.com/news-releases/evogene-and-shanghai-lishan-biopharmaceuticals-co-announce-exclusive-licensing-agreement-for-bmc128-a-microbiome-based-therapeutic-for-renal-and-lung-cancer-302678749.html) for BMC128, a first-in-class microbiome-based therapeutic targeting re
The AllSci Brief
Systematic R&D and deal news. Daily.